• About
  • Masthead
  • License Content
  • Advertise
  • Press Releases
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

Sign in
SUBSCRIBE
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
  • Partners
    • License Content
    • Advertise with Us
2 Minute Medicine
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
  • Partners
    • License Content
    • Advertise with Us
Sign in
SUBSCRIBE
2 Minute Medicine
Sign in
Subscribe
✦ EvidencePulse™ by 2 Minute Medicine 2026 evidence scan 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... ↑ Try EvidencePulse™ Ask the evidence.
Get the signal. Try it now → Physician-trained medical AI by 2 Minute Medicine
Home StudyGraphics

#VisualAbstract: Carfilzomib, dexamethasone, and lenalidomide superior to lenalidomide monotherapy for multiple myeloma

byTeddy Guo
April 5, 2023
in StudyGraphics
Reading Time: 1 min read
#VisualAbstract: Carfilzomib, dexamethasone, and lenalidomide superior to lenalidomide monotherapy for multiple myeloma
Share on FacebookShare on TwitterShare on LinkedIn

Click to read this study in The Lancet Oncology. 

RELATED REPORTS

Anitocabtagene autoleucel associated with sustained clinical response in heavily pretreated multiple myeloma

Intraarterial dexamethasone may be effective for pain relief following uterine fibroid embolization

Tags: blood cancercarfilzomibdexamethasonehematologic malignancyhematologylenalidomidemultiple myeloma
Previous Post

Antidepressants may improve symptoms in patients with inflammatory bowel disease

 Next Post

Cardiac arrest survival during delivery lowest in those with disseminated intravascular coagulation

RelatedReports

Abstract representation of hematological cells with a fluid bag and pill, indicating targeted therapy for leukemia or multiple myeloma.
Chronic Disease

Anitocabtagene autoleucel associated with sustained clinical response in heavily pretreated multiple myeloma

September 28, 2026
Elagolix with add-back hormone therapy effective in reducing fibroid-associated menstrual bleeding
Chronic Disease

Intraarterial dexamethasone may be effective for pain relief following uterine fibroid embolization

August 5, 2026
Elagolix with add-back hormone therapy effective in reducing fibroid-associated menstrual bleeding
Weekly Rewinds

2 Minute Medicine Rewind August 3rd, 2026

August 3, 2026
Combined lenalidomide and rituximab dose escalation found to be safe for CLL
All Specialties

Venetoclax (Venclyxto) expands treatment options as chronic lymphocytic leukemia care moves further from chemotherapy

June 8, 2026
Next Post

Cardiac arrest survival during delivery lowest in those with disseminated intravascular coagulation

Fish oil and aspirin did not reduce arteriovenous fistula failure: The FAVOURED trail

Incongruency between patients’ values and comfort-focused care on maintenance dialysis

The American Heart Association's Life Essential 8 scores to predict cardiovascular health

✦ EvidencePulse™ by 2 Minute Medicine 2026 evidence scan 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... Try EvidencePulse™ Get the signal. Try it now → Physician-trained medical AI by 2 Minute Medicine

2MM+ All Access

Full details →
$4.99 /month

3-day free trial · cancel anytime

  • ✓100+ physician-written reports
  • ✓EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

NPI Lookup · Free

Look up any US clinician

Search by name or NPI number, live from the CMS NPI Registry.

  • OIG exclusion check
  • Licenses and specialties
  • No account needed
Open NPI Lookup →

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Children with autism spectrum disorder may have reduced fecal microbial diversity
  • Variable homicide mortality rates among women aged 15-44 years depending on state abortion policy
  • An artificial intelligence model demonstrates the potential for improving the efficiency of structural heart disease screening using electrocardiograms
License Content
Terms of Use | Disclaimer
Cookie Policy
2MM+ All Access Full details →

The medical literature, distilled daily.

Monthly plan selected: $4.99 /month.

$4.99/month

3-day free trial · cancel anytime

Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

Yearly plan selected: $49.90 /year.

$49.90/year

2 months free

Start 3-day free trial

Then $49.90/year.

Membership benefits

  • ✓100+ physician-written reports
  • ✓AI EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
  • ✓NPI watchlist + bulk NPI verification

Already a member? Sign in

  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
  • Partners
    • License Content
    • Advertise with Us
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.